Royce & Associates LP continued to hold its stake in Cerus Corporation (NASDAQ:CERS) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 248,000 shares of the biotechnology company’s stock at the end of the second quarter. Royce & Associates LP owned about 0.24% of Cerus Corporation worth $622,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently made changes to their positions in the stock. Teachers Advisors LLC increased its stake in Cerus Corporation by 0.4% in the fourth quarter. Teachers Advisors LLC now owns 269,964 shares of the biotechnology company’s stock valued at $1,174,000 after acquiring an additional 1,152 shares during the last quarter. Stephens Inc. AR increased its stake in Cerus Corporation by 0.3% in the first quarter. Stephens Inc. AR now owns 950,729 shares of the biotechnology company’s stock valued at $4,231,000 after acquiring an additional 2,539 shares during the last quarter. American International Group Inc. increased its stake in Cerus Corporation by 7.1% in the first quarter. American International Group Inc. now owns 62,374 shares of the biotechnology company’s stock valued at $278,000 after acquiring an additional 4,127 shares during the last quarter. Metropolitan Life Insurance Co. NY increased its stake in Cerus Corporation by 7.9% in the first quarter. Metropolitan Life Insurance Co. NY now owns 81,132 shares of the biotechnology company’s stock valued at $361,000 after acquiring an additional 5,920 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its stake in Cerus Corporation by 1.3% in the first quarter. Bank of New York Mellon Corp now owns 505,652 shares of the biotechnology company’s stock valued at $2,250,000 after acquiring an additional 6,710 shares during the last quarter. 58.26% of the stock is currently owned by institutional investors and hedge funds.

Shares of Cerus Corporation (CERS) opened at 2.63 on Monday. The firm’s 50 day moving average is $2.49 and its 200-day moving average is $3.08. The company’s market cap is $287.03 million. Cerus Corporation has a 1-year low of $1.93 and a 1-year high of $6.59.

Cerus Corporation (NASDAQ:CERS) last issued its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.16) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.16). The firm had revenue of $9.53 million for the quarter, compared to analyst estimates of $9.14 million. Cerus Corporation had a negative net margin of 164.39% and a negative return on equity of 120.31%. The business’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.18) EPS. Equities analysts expect that Cerus Corporation will post ($0.68) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by Watch List News and is the property of of Watch List News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at https://www.watchlistnews.com/royce-associates-lp-maintains-holdings-in-cerus-corporation-cers/1570188.html.

A number of research analysts recently issued reports on the stock. BidaskClub raised shares of Cerus Corporation from a “sell” rating to a “hold” rating in a research note on Tuesday, August 8th. Cantor Fitzgerald reissued a “buy” rating and issued a $7.00 price objective on shares of Cerus Corporation in a research note on Wednesday, June 7th. ValuEngine cut shares of Cerus Corporation from a “sell” rating to a “strong sell” rating in a research note on Saturday, June 17th. Zacks Investment Research cut shares of Cerus Corporation from a “hold” rating to a “sell” rating in a research note on Friday, May 26th. Finally, BTIG Research reissued a “buy” rating and issued a $5.00 price objective on shares of Cerus Corporation in a research note on Sunday, May 28th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $7.25.

In related news, insider Laurence M. Corash purchased 92,796 shares of the firm’s stock in a transaction dated Friday, August 11th. The shares were purchased at an average price of $2.45 per share, with a total value of $227,350.20. Following the acquisition, the insider now directly owns 1,375,711 shares of the company’s stock, valued at $3,370,491.95. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. 7.40% of the stock is owned by corporate insiders.

Cerus Corporation Profile

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Want to see what other hedge funds are holding CERS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cerus Corporation (NASDAQ:CERS).

Institutional Ownership by Quarter for Cerus Corporation (NASDAQ:CERS)

Receive News & Ratings for Cerus Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.